Early body composition changes in trans women on low-dose estradiol: comparing oral vs sublingual administration using dual energy absorptiometry and bioelectrical impedance analysis.
Iris Yaish, Assaf Buch, Guy Gindis, Yael Sofer, Mira Arbiv, Yaffa Moshe, Yona Grenman, Karen Tordjman
{"title":"Early body composition changes in trans women on low-dose estradiol: comparing oral vs sublingual administration using dual energy absorptiometry and bioelectrical impedance analysis.","authors":"Iris Yaish, Assaf Buch, Guy Gindis, Yael Sofer, Mira Arbiv, Yaffa Moshe, Yona Grenman, Karen Tordjman","doi":"10.1093/jsxmed/qdaf005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Low-dose sublingual estradiol gender-affirming hormone therapy (GAHT) in treatment-naive transgender women effectively suppresses testosterone and initiates breast development, comparable to oral estradiol with cyproterone acetate; however, its impact on body composition remains unstudied.</p><p><strong>Aim: </strong>To assess early body composition changes with low-dose estradiol, compare sublingual versus oral administration efficacy, and evaluate bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) agreement in transgender women undergoing GAHT.</p><p><strong>Methods: </strong>In this 6-month prospective study, 22 treatment-naïve transgender women received either 2 mg/day sublingual estradiol (SLE) or combined oral (CO)-2 mg/day oral estradiol plus 10 mg/day cyproterone acetate. Body composition was assessed using DXA and BIA at baseline and after 6 months.</p><p><strong>Outcomes: </strong>Changes in body composition, including lean body mass, fat mass, visceral fat area, waist-to-hip ratio, and android-to-gynoid fat ratio.</p><p><strong>Results: </strong>BIA and DXA measurements showed good agreement. Both groups experienced decreased lean body mass and increased fat mass. The SLE group showed less increase in total and segmental body fat, and visceral fat area compared to CO. Both treatments decreased waist-to-hip ratio and android-to-gynoid fat ratio, indicating early achievement of a more feminine body shape.</p><p><strong>Clinical implications: </strong>These findings may help optimize GAHT protocols, improve patient satisfaction with treatment, and enable monitoring outcome assessment in transgender women.</p><p><strong>Strengths and limitations: </strong>This study provides valuable insights into early body composition changes with low-dose estradiol administration via different administration routes and validates BIA as an alternative to DXA. However, the sample size was relatively small, the study arm allocation was not randomized, and the study duration was only 6 months.</p><p><strong>Conclusion: </strong>Low-dose estradiol induces significant feminizing body composition changes within 6 months of GAHT, with sublingual administration potentially limiting fat accumulation while achieving a feminine body shape.</p><p><strong>Study registration: </strong>ISRCTN15726488 Entire data set found at: https://doi.org/10.17605/OSF.IO/VNC54.</p>","PeriodicalId":51100,"journal":{"name":"Journal of Sexual Medicine","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Sexual Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jsxmed/qdaf005","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Low-dose sublingual estradiol gender-affirming hormone therapy (GAHT) in treatment-naive transgender women effectively suppresses testosterone and initiates breast development, comparable to oral estradiol with cyproterone acetate; however, its impact on body composition remains unstudied.
Aim: To assess early body composition changes with low-dose estradiol, compare sublingual versus oral administration efficacy, and evaluate bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) agreement in transgender women undergoing GAHT.
Methods: In this 6-month prospective study, 22 treatment-naïve transgender women received either 2 mg/day sublingual estradiol (SLE) or combined oral (CO)-2 mg/day oral estradiol plus 10 mg/day cyproterone acetate. Body composition was assessed using DXA and BIA at baseline and after 6 months.
Outcomes: Changes in body composition, including lean body mass, fat mass, visceral fat area, waist-to-hip ratio, and android-to-gynoid fat ratio.
Results: BIA and DXA measurements showed good agreement. Both groups experienced decreased lean body mass and increased fat mass. The SLE group showed less increase in total and segmental body fat, and visceral fat area compared to CO. Both treatments decreased waist-to-hip ratio and android-to-gynoid fat ratio, indicating early achievement of a more feminine body shape.
Clinical implications: These findings may help optimize GAHT protocols, improve patient satisfaction with treatment, and enable monitoring outcome assessment in transgender women.
Strengths and limitations: This study provides valuable insights into early body composition changes with low-dose estradiol administration via different administration routes and validates BIA as an alternative to DXA. However, the sample size was relatively small, the study arm allocation was not randomized, and the study duration was only 6 months.
Conclusion: Low-dose estradiol induces significant feminizing body composition changes within 6 months of GAHT, with sublingual administration potentially limiting fat accumulation while achieving a feminine body shape.
Study registration: ISRCTN15726488 Entire data set found at: https://doi.org/10.17605/OSF.IO/VNC54.
期刊介绍:
The Journal of Sexual Medicine publishes multidisciplinary basic science and clinical research to define and understand the scientific basis of male, female, and couples sexual function and dysfunction. As an official journal of the International Society for Sexual Medicine and the International Society for the Study of Women''s Sexual Health, it provides healthcare professionals in sexual medicine with essential educational content and promotes the exchange of scientific information generated from experimental and clinical research.
The Journal of Sexual Medicine includes basic science and clinical research studies in the psychologic and biologic aspects of male, female, and couples sexual function and dysfunction, and highlights new observations and research, results with innovative treatments and all other topics relevant to clinical sexual medicine.
The objective of The Journal of Sexual Medicine is to serve as an interdisciplinary forum to integrate the exchange among disciplines concerned with the whole field of human sexuality. The journal accomplishes this objective by publishing original articles, as well as other scientific and educational documents that support the mission of the International Society for Sexual Medicine.